The UK's Food Safety Authority responds to questions from industry about its new CBD compliance rules.
The UK’s Food Safety Authority has clarified in a Q&A with the country’s Association for the Cannabinoid Industry the conditions for cannabidiol (CBD) food supplement compliance.
Earlier this year, the FSA gave companies selling CBD food supplements in the UK until 31 March 2021 to hold...
Warning letters to SuXiang Medical Instrument in China and Yahon Enterprise in Vietnam among recent warnings FDAS sent to OTC drug and supplement manufacturers, including a Florida firm, White Label Leaf, warned about selling gummies containing delta-8 THC, and other OTC skin care product firms.
Attorneys discuss potential impacts on consumer health products industry from Supreme Court’s “Loper Bright” decision in June on litigation brought by two fisheries, Loper Bright v. Raimondo and Relentless v. Department of Commerce.
Noting similar warnings a year ago, the FDA and FTC announce warnings to six more, part of a joint effort to stop sales of copycat food products containing delta-8 THC, saying companies selling these "illegal products are demonstrating complete neglect for consumer safety.”
Committee’s report published with FY2025 appropriation states a different approach to establishing FDA regulation of non-drug products containing hemp as a derivative of cannabis de-scheduled as controlled substance in the US since 2018.
Mentholatum says two line extensions made with 2% salicylic acid and its "Oxy for Every Kind of Ne" campaign reinforce the brand’s “commitment to tackling every type of acne—from face-ne and chin-ne to body-ne.”
David Ball moves from Bayer’s North America business to be Perrigo’s first chief brand and digital officer. He joins CEO who also moved to Perrigo from Bayer with decades of branded product experience.
The Fragrance Creators Association president and CEO discusses the group’s vision for fragrance industry stewardship and opportunities provided by AI, biotechnology and wellness trends in an exclusive Q&A with HBW Insight.
